Seagle, Emma E

The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic

Seagle, E. E., Jackson, B. R., Lockhart, S. R., Georgacopoulos, O., Nunnally, N. S., Roland, J., Barter, D. M., Johnston, H. L., Czaja, C. A., Kayalioglu, H., et al. (2022) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityCOVID-19 Clinical Research Studies

Cited by 141

Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities ― Texas and the District of Columbia, January–April 2021

Lyman, M., Forsberg, K., Reuben, J., Dang, T., Free, R., Seagle, E. E., Sexton, D. J., Soda, E., Jones, H., Hawkins, D., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

Antifungal resistance and susceptibilityInfection Control in Healthcare

Cited by 104

Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine

Seagle, E. E., Bednarczyk, R. A., Hill, T., Fiebelkorn, A. P., Hickman, C. J., Icenogle, J. P., Belongia, E. A., & McLean, H. Q. (2018) · Vaccine

Virology and Viral DiseasesImmune responses and vaccinations

Cited by 92

Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018.

Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 20